Sex hormone receptor repertoire in breast cancer.
Sex hormone receptor repertoire in breast cancer.
复制标题
DOI：
10.1155/2013/284036
复制
发表时间：
2013
影响因子：
1.9
通讯作者：
Fell RG
中科院分区：
文献类型：
--
作者：
Higa GM;Fell RG
乳腺癌分类为内分泌敏感型、激素依赖性型或雌激素受体 (ER) 阳性，特指 ERα。 ERα 介导的信号传导的破坏是最古老的公认肿瘤靶点之一，被认为是用于治疗这种疾病的所有激素干预措施的作用机制模式。虽然 ERα 被广泛认为是最重要的单一预测因素（对于内分泌治疗的反应），但肿瘤细胞中受体的存在也具有预后价值。尽管另外两种性激素受体（即 ERβ 和雄激素受体）的临床相关性仍不清楚，但在激素依赖性乳腺癌中观察到的两种不一致现象可能与 ERβ 介导的效应和雄激素作用存在因果关系。尽管如此，我们对调节分子和耐药机制的理解仍然不完整，这进一步损害了我们开发可以改善疾病结果的新型治疗策略的能力。本综述重点关注乳腺癌中性激素受体介导的作用。
Classification of breast cancer as endocrine sensitive, hormone dependent, or estrogen receptor (ER) positive refers singularly to ERα. One of the oldest recognized tumor targets, disruption of ERα-mediated signaling, is believed to be the mechanistic mode of action for all hormonal interventions used in treating this disease. Whereas ERα is widely accepted as the single most important predictive factor (for response to endocrine therapy), the presence of the receptor in tumor cells is also of prognostic value. Even though the clinical relevance of the two other sex hormone receptors, namely, ERβ and the androgen receptor remains unclear, two discordant phenomena observed in hormone-dependent breast cancers could be causally related to ERβ-mediated effects and androgenic actions. Nonetheless, our understanding of regulatory molecules and resistance mechanisms remains incomplete, further compromising our ability to develop novel therapeutic strategies that could improve disease outcomes. This review focuses on the receptor-mediated actions of the sex hormones in breast cancer.